Heart failure and pulmonary hypertension.

Area of Science:

• Cardiovascular Medicine
• Pulmonary Medicine
• Molecular Biology

Background:

• Pulmonary hypertension (PH) combined with right ventricular dysfunction significantly worsens heart failure prognosis.
• Current treatments targeting the nitric oxide pathway, such as PDE5 inhibition, improve symptoms and functional capacity in PH patients.
• Emerging research implicates Bone Morphogenetic Protein Receptor 2 (BMPR2) signaling in the pathophysiology of PH.

Purpose of the Study:

• To review the impact of PH and right ventricular dysfunction on heart failure.
• To discuss novel therapeutic strategies targeting nitric oxide and BMP signaling pathways.
• To highlight the need for further research into long-term outcomes and mechanisms of PH treatments.

Main Methods:

• Literature review of current clinical strategies and basic science research in PH.
• Analysis of the role of nitric oxide and BMP signaling in PH.
• Discussion of potential future therapeutic targets.

Main Results:

• Nitric oxide pathway modulation improves functional capacity and symptoms in heart failure with PH.
• BMPR2 mutations and decreased expression are linked to familial and secondary forms of PH, respectively.
• BMP signaling is crucial in the underlying pathophysiology of PH.

Conclusions:

• Targeting nitric oxide pathways offers symptomatic relief for PH patients.
• BMP signaling pathways represent a promising area for novel therapeutic development in PH.
• Further investigation is required to understand the long-term impact and precise mechanisms of current and future PH therapies.